Show simple item record

dc.contributor.authorNuñez, Julio
dc.contributor.authorPalau, Patricia
dc.contributor.authorDomínguez Mafé, Eloy
dc.contributor.authorMollar, Anna
dc.contributor.authorNuñez, Eduardo
dc.contributor.authorRamón, José María
dc.contributor.authorMiñana, Gema
dc.contributor.authorSantas, Enrique
dc.contributor.authorFácila, Lorenzo
dc.contributor.authorGórriz, José L.
dc.contributor.authorSanchis, Juan
dc.contributor.authorBayés‐Genís, Antoni
dc.identifier.citationNUÑEZ, Julio; PALAU SAMPIO, Patricia; DOMÍNGUEZ MAFÉ, Eloy; MOLLAR, Anna; NUÑEZ, Eduardo; RAMÓN, José María; MIÑANA, Gema; SANTAS, Enrique; FÁCILA, Lorenzo; GÓRRIZ, José L.; SANCHIS, Juan; BAYÉS-GENÍS, Antoni, (2018). Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study. Clinical Cardiology, v. 41, issue 4, p. 476-480ca_CA
dc.description.abstractBackground: Sodium-glucose linked transporter 2 inhibition recently emerged as a promising ther- apy for reducing the risk of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). However, there is a lack of data endorsing its role in symptomatic HF patients. We sought to eval- uate the short-term effects of empagliflozin on maximal exercise capacity in these patients. Hypothesis: We postulate tretament with empagliflozin may improve functional capacity in patients with T2DM and established HF. Methods: Nineteen T2DM patients with symptomatic HF were prospectively included and underwent cardiopulmonary exercise testing before and 30 days after initiation of empagliflo- zin therapy. A mixed-effects model for repeated measures was used. Results: Median patient age was 72 years (interquartile range, 60–79 years); 42.1% were in New York Heart Association class III. Baseline mean ( SD) peak oxygen consum ption (peak VO 2 ) was 10.9  4. 0 mL/ min /k g. P eak VO 2 increased significantly at 30 days (∆: +1.21 [0.66 to 1.76] mL/min/kg; P < 0.001). A significant improvement in ventilatory efficiency during exercise, 6-minute walking distance, and quality of life, and a reduction in antigen carbohydrate 125, were also found. Estimated glomerular filtration rate and natriuretic peptides did not significantly change. Conclusions: In this pilot study, empagliflozin was associated with 1-month improvement in exercise capacity in T2DM patients with symptomatic HF. This beneficial effect was also found for other surrogates of severity.ca_CA
dc.format.extent5 p.ca_CA
dc.subjectExercise Capacityca_CA
dc.subjectHeart Failureca_CA
dc.titleEarly effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study.ca_CA
dc.relation.projectIDThis work was supported in part by grants from CIBER Cardiovascular (16/11/00420, 16/11/00403), FEDER, and PIE (15/00013).

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record